<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11168">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02961556</url>
  </required_header>
  <id_info>
    <org_study_id>AJG555/CT2</org_study_id>
    <nct_id>NCT02961556</nct_id>
  </id_info>
  <brief_title>General Clinical Study of AJG555 in Pediatric Patients With Chronic Constipation</brief_title>
  <official_title>General Clinical Study of AJG555 in Pediatric Patients With Chronic Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EA Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This baseline-controlled, open-label, multicenter study evaluates the efficacy and safety of
      AJG555 orally administered for 2 weeks in pediatric participants with chronic constipation.
      The safety and efficacy of 12 weeks of administration will also be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from the second week of the screening period in the number of spontaneous bowel movements (SBMs) at the second week of the administration period</measure>
    <time_frame>Screening; Week 2 of administration period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from the second week of the screening period in the number of SBMs at each week of the administration period</measure>
    <time_frame>Screening; up to Week 12 of administration period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from the second week of the screening period in the number of complete SBMs (CSBMs) at each week of the administration period</measure>
    <time_frame>Screening; up to Week 12 of administration period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from the screening period in the number of SBMs at two weeks after the initiation of the administration</measure>
    <time_frame>Screening; Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from the screening period in the number of CSBMs at two weeks after the initiation of the administration</measure>
    <time_frame>Screening; Week 2 of administration period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days until SBM and CSBM</measure>
    <time_frame>up to Week 12 of administration period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from the second week of the screening period in the total number of SBMs at each week of the administration period</measure>
    <time_frame>Screening; up to Week 12 of administration period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders for SBM and CSBM at each week of the administration period</measure>
    <time_frame>up to Week 12 of administration period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool consistency measured by the Bristol stool form scale</measure>
    <time_frame>up to Week 12 of administration period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usage of rescue medication</measure>
    <time_frame>up to Week 12 of administration period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pouches of AJG555 administered</measure>
    <time_frame>up to Week 12 of administration period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of administration of AJG555</measure>
    <time_frame>up to Week 12 of administration period</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Chronic Constipation</condition>
  <arm_group>
    <arm_group_label>AJG555</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After 2 weeks of the screening period, participants will be administered AJG555 starting on the day of the formal enrollment and continuing for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AJG555</intervention_name>
    <description>Participants will receive 1 to 6 sachets daily per participants' age and conditions.</description>
    <arm_group_label>AJG555</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Main Inclusion Criteria:

          -  Participants with chronic constipation

          -  Age: 2 years old or older and 14 years old or younger (at the time of the informed
             consent)

          -  Gender: N/A

        Exclusion Criteria:

        Main Exclusion Criteria:

          -  Participants with organic constipation or participants suspected of having organic
             constipation

          -  Participants with symptomatic constipation or participants suspected of having
             symptomatic constipation

          -  Participants with drug-induced constipation or participants suspected of having
             drug-induced constipation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bunkyo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hutyu</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ohta</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Setagaya</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 27, 2017</lastchanged_date>
  <firstreceived_date>November 9, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AJG555</keyword>
  <keyword>Constipation</keyword>
  <keyword>Phase 3</keyword>
  <keyword>Pediatric participants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
